Article Details
Retrieved on: 2024-09-26 06:38:28
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article highlights Pfizer's decision to withdraw OXBRYTA for sickle cell disease due to safety concerns, mentioning its impact in treating a major health issue like sickle cell prevalent in Africa and reinforcing the integral role of the pharmaceutical industry in capital markets.
Article found on: pipelinereview.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here